There have been lots of expert voices around pandemic-related learnings and regulatory adjustments that have the potential to stick as the world seeks to crawl back to some semblance of normalcy as COVID-19 vaccination gathers pace.
Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways
Collaborations, Agility Also Key
Amgen CEO Robert Bradway spotlights opportunities to up the tempo of drug discovery and development, drawing from the success of COVID-19 vaccines, and touches on the company's breakthrough treatment Lumakras and efforts in gastric cancer.
More from COVID-19
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.